Medical devices, healthcare technology and the business of care
PMA approval · P250041

SELUTION SLR 014 PTCA Drug-Eluting Balloon

MedAlliance, LLC · Decision date Sep 18, 2026

FDA DECISIONP250041

What did the FDA approve?

FDA records P250041 as an original PMA application. The recorded decision is approval, dated Sep 18, 2026.

FDA approval order statement

The SELUTION SLR 014 PTCA Drug-Eluting Balloon is intended to be used after appropriate vessel preparation in patients undergoing percutaneous coronary intervention (PCI) in coronary arteries 2.25 mm to 4.50 mm in diameter and lesions <= 26 mm in length for the purpose of improving myocardial perfusion when treating in-stent restenosis (ISR).
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Sep 18, 2026

FDA source record

Regulatory record facts

Identifier
P250041
Regulatory pathway
Premarket approval application
Product code
OOB
Decision code
APPR
Decision date
Sep 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug-eluting percutaneous transluminal coronary angioplasty catheter.

Product code
OOB
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250041 received

    Application receipt date recorded by FDA.

  2. P250041 · FDA decision

    APPR

  3. P250041/S001 · Related supplement

    SELUTION SLR 014 PTCA Drug-Eluting Balloon

Timeline entries are records held by MedtechLedger for P250041. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250041

Product / regulatory recordCompanyPathwayDecision dateSource
MedAlliance, LLCPMA supplementNov 6, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

MedAlliance, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4 Jenner, Suite 190, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records